Table 1.
Clinical Characteristics Of Patients Treated With Definitive Radiotherapy For Early Stage NSCLC (N = 234)
| Characteristics | Control* (n=64) | COPD (n=132) | CPFE (n=16) | IPF (n=22) | P Value |
|---|---|---|---|---|---|
| Age (years) | 78.5 (74.0–81.5) | 75.0 (71.0–79.0) | 76.0 (74.0–79.0) | 74.5 (72.0–79.0) | 0.036 |
| Sex Female Male |
30 (46.9%) 34 (53.1%) |
15 (11.4%) 117 (88.6%) |
0 (0%) 16 (100%) |
0 (0%) 22 (100%) |
<0.001 |
| Smoking Status Never smoker Current or Ex-smoker Pack-years† |
34 (53.1%) 30 (46.9%) 45 (30–60) |
15 (11.4%) 117 (88.6%) 40 (30–55) |
0 (0%) 16 (100%) 40 (25–50) |
0 (0%) 22 (100%) 40 (30–59) |
<0.001 |
| ECOG performance status 0–1 2–3 |
45 (70.3%) 19 (29.7%) |
92 (69.7%) 40 (30.3%) |
9 (56.3%) 7 (43.7%) |
13 (59.1%) 9 (40.9%) |
0.542 |
| Clinical Stage IA-IB IIA-IIB |
48 (75.0%) 16 (25.0%) |
96 (72.7%) 36 (27.3%) |
11 (68.8%) 5 (31.2%) |
15 (68.2%) 7 (31.8%) |
0.914 |
| Histology Adenocarcinoma Squamous cell carcinoma Others Not proven |
28 (43.8%) 21 (32.8%) 4 (6.3%) 11 (17.1%) |
31 (23.5%) 75 (56.8%) 7 (5.3%) 19 (14.4%) |
2 (12.5%) 7 (43.8%) 1 (6.3%) 6 (37.4%) |
5 (22.7%) 10 (45.5%) 1 (4.5%) 6 (27.3%) |
0.02 |
| Pulmonary Function Test | |||||
| FVC, L | 2.6 (2.1–3.0) | 3.0 (2.5–3.5) | 3.4 (3.1–3.8) | 3.1 (2.9–3.8) | <0.001 |
| FVC, % pred | 82.0 (71.5–92.5) | 80.5 (67.5–90.5) | 88.0 (78.5–94.0) | 83.0 (74.0–89.0) | 0.284 |
| FEV1, L | 2.0 (1.6–2.4) | 1.5 (1.2–1.9) | 2.2 (2.0–2.5) | 2.2 (2.1–2.6) | <0.001 |
| FEV1, % pred | 95.5 (80.5–112.0) | 64.0 (46.0–75.5) | 82.0 (75.0–102.0) | 85.5 (80.0–97.0) | <0.001 |
| FEV1/FVC, % | 77.0 (74.0–81.5) | 55.0 (44.0–63.0) | 63.0 (60.0–73.5) | 71.5 (67.0–76.0) | <0.001 |
| DLco, % pred‡ | 80.0 (68.0–93.0) | 67.0 (54.5–87.0) | 55.0 (45.0–65.0) | 56.0 (44.0–66.5) | <0.001 |
| FEV1 ≤ 80% pred | 16 (25.0%) | 107 (81.1%) | 5 (31.3%) | 6 (27.3%) | <0.001 |
| FEV1 ≤ 50% pred | 1 (1.6%) | 45 (34.1%) | 1 (6.2%) | 1 (4.5%) | <0.001 |
| DLco ≤ 80% pred‡ | 27 (50.9%) | 77 (66.4%) | 13 (86.7%) | 19 (95.0%) | <0.001 |
| DLco ≤ 60% pred‡ | 7 (13.2%) | 42 (36.2%) | 11 (73.3%) | 13 (65.0%) | <0.001 |
| Radiotherapy technique 3DCRT/IMRT SBRT |
37 (57.8%) 27 (42.2%) |
85 (64.4%) 47 (35.6%) |
7 (43.8%) 9 (56.2%) |
14 (63.6%) 8 (36.4%) |
0.395 |
| Radiotherapy planning parameters for total lung volume Mean dose (cGy) V5 (%) V20 (%) |
836.0 (544.4–1104.9) 27.0 (20.9–36.5) 14.7 (9.1–20.4) |
769.6 (560.2–1052.3) 29.1 (22.7–36.8) 13.6 (9.5–18.5) |
632.6 (498.3–1007.3) 27.2 (19.3–33.3) 11.5 (7.9–18.0) |
708.1 (608.9–987.6) 27.9 (25.1–33.2) 11.9 (9.0–18.2) |
0.714 0.822 0.249 |
Notes: Data are presented as number (%) or median (interquartile range). *Non-COPD, non-CPFE, and non-IPF. †Pack-year was calculated among 185 current or ex-smokers. ‡DLco was available in 204 patients.
Abbreviations: 3DCRT, 3-dimensional conformal radiation therapy; COPD, chronic obstructive pulmonary disease; CPFE, combined pulmonary fibrosis and emphysema; ECOG, Eastern Cooperative Oncology Group; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second; IMRT, intensity-modulated radiation therapy; IPF, idiopathic pulmonary fibrosis; NSCLC, non-small cell lung cancer; SBRT, stereotactic body radiation therapy; VD, percentage volume of organ receiving ≥ D Gy.